{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:04:45Z","timestamp":1790874285511,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Haemophilia impacts health and quality of life. Advances in treatments such as factor replacement therapy (FRT), bispecific monoclonal antibody (BS\u2010mAb), gene therapy (GT), rebalancing treatment and high sustained factor necessitate understanding patient preferences to inform therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study quantified trade\u2010offs of French adult patients with moderate\u2010to\u2010severe haemophilia A\/B when choosing between two treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A non\u2010interventional, web\u2010based survey using the threshold technique was conducted. Six treatment attributes were identified through systematic review, semi\u2010structured patient interviews and clinical expert consultations: administration frequency, number of annual bleeds, duration of prophylaxis discontinuation, duration of long\u2010term safety data, joint pain after 6 months and preparation\/administration requirements. Thresholds were interpreted under fixed attributes assumptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 95 recruited patients, 86 were eligible for analysis. Most participants were male (97%), aged 41 on average; 88% had haemophilia A, 87% severe cases. On average, patients accepted 1.1 (median: 0) annual bleeds to switch from BS\u2010mAb\u2010like to high sustained factor\u2010like profiles, 1.5 (median: 0.5) to switch from BS\u2010mAb\u2010like to rebalancing treatment\u2010like profiles and 3.3 to switch from FRT\u2010like to rebalancing treatment\u2010like profiles, holding all else constant. To switch from FRT\u2010like to GT\u2010like profile, patients were willing to accept 4.8 annual bleeds or 12.5 years of prophylaxis discontinuation (median: 1). Patients required lower annual bleeds and longer prophylaxis discontinuation when switching from BS\u2010mAb\u2010like to GT\u2010like profile (3.5 annual bleeds or 14.3 years of prophylaxis discontinuation [median: 2]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment preferences among French patients with haemophilia are highly individualized, reflecting nuanced trade\u2010offs between bleeding risk, treatment convenience and long\u2010term safety that vary according to current therapeutic strategies and individual patient priorities. These findings underscore the importance of shared, personalized decision\u2010making in contemporary haemophilia care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70298","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:11:22Z","timestamp":1789110682000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Preferences for the Treatment of Haemophilia A and B in France"],"prefix":"10.1111","author":[{"given":"Yesim","family":"Dargaud","sequence":"first","affiliation":[{"name":"French Reference Center for Hemophilia Louis Pradel Cardiology Hospital UR4609 Hemosatsis &amp; Thrombosis Research Unit University of Lyon 1  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Fahfouhi","sequence":"additional","affiliation":[{"name":"Pfizer  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Ezzalfani","sequence":"additional","affiliation":[{"name":"Amaris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Foix","family":"Colonier","sequence":"additional","affiliation":[{"name":"Amaris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaeddine","family":"Sidhom","sequence":"additional","affiliation":[{"name":"Amaris  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Amaris  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Rudant","sequence":"additional","affiliation":[{"name":"Pfizer  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Kessouri","sequence":"additional","affiliation":[{"name":"Pfizer  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Giraud","sequence":"additional","affiliation":[{"name":"AFH: French Association of Hemophiliacs  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Guillet","sequence":"additional","affiliation":[{"name":"CRH, CRC\u2010MHC (Haemophilia Reference Center, Resource and Competence Center for Constitutional Hemorrhagic Diseases), University Hospital &amp; Rennes University, University Hospital, Inserm, Ehesp, Irset (Institute for Research in Health, Environment and Work) &amp; Umr_s 1085  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Reynaud","sequence":"additional","affiliation":[{"name":"Pfizer  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"StatPearls","author":"Mehta P.","year":"2023"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"issue":"6","key":"e_1_2_11_4_1","first-page":"S112","article-title":"Current Challenges in the Management of Hemophilia","volume":"21","author":"Bauer K. A.","year":"2015","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19\u20101208"},{"key":"e_1_2_11_6_1","unstructured":"I.Hoppenot \u201cH\u00e9mophilie: Une Nouvelle \u00e8re Th\u00e9rapeutique.\u201d (VIDAL;2023) accessed March 13 2024 https:\/\/www.vidal.fr\/actualites\/30341\u2010hemophilie\u2010une\u2010nouvelle\u2010ere\u2010therapeutique.html."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2004.05168.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102516.2003.00780.x"},{"key":"e_1_2_11_9_1","unstructured":"World Federation of Hemophilia (WFH) \u201cHemostatic Rebalancing Therapy \u201d accessed February 13 2025 https:\/\/www1.wfh.org\/publications\/files\/pdf\u20102367.pdf."},{"key":"e_1_2_11_10_1","unstructured":"World Federation of Hemophilia (WFH) \u201cClotting Factor Replacement Therapies \u201d accessed February 13 2025 https:\/\/www1.wfh.org\/publications\/files\/pdf\u20102365.pdf."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010018\u20100734\u20102"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258\u2010019\u201000521\u20103"},{"key":"e_1_2_11_14_1","unstructured":"M.Ezzalfani P.Roukoz A.Reynaud et al. \u201cUne Revue Syst\u00e9matique De La Litt\u00e9rature Sur Les Attributs De Traitements Dans Les \u00e9tudes De Pr\u00e9f\u00e9rence En H\u00e9mophilie A Et B\u201d Book des abstracts CFH 2024 Abstract 00066(2024) accessed May 13 2025 https:\/\/www.congres\u2010hemostase.com\/wp\u2010content\/uploads\/2024\/extern\/CFH%202024_Book\u2010abstracts_Final.pdf#page=42."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14401"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911\u2010020\u201001142\u2010w"},{"key":"e_1_2_11_17_1","unstructured":"U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health Center for Biologics Evaluation and Research \u201cPatient Preference Information\u2014Voluntary Submission Review in Premarket Approval Applications Humanitarian Device Exemption Applications and De Novo Requests and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry FDA Staff and Other Stakeholders \u201d2016 https:\/\/www.fda.gov\/media\/92593\/download."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010018\u20100468\u20107"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:25:40Z","timestamp":1790871940000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":17,"alternative-id":["10.1111\/hae.70298"],"URL":"https:\/\/doi.org\/10.1111\/hae.70298","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2025-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hae.70298"}}